|
1
|
Park S, Kario K, Park CG, Huang QF, Cheng
HM, Hoshide S, Wang JG and Chen CH; Characteristics On the
ManagEment of Hypertension in Asia-Morning Hypertension Discussion
Group (COME Asia MHDG), : Target blood pressure in patients with
diabetes: Asian perspective. Yonsei Med J. 57:1307–1311. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bays H, Gao P, Völker B, Mattheus M,
Ruilope LM and Zhu D: Efficacy of single-pill combination of
telmisartan 80 mg and hydrochlorothiazide 25 mg in patients with
cardiovascular disease risk factors: A prospective subgroup
analysis of a randomized, double-blind, and controlled trial. Int J
Hypertens. 2013:7498302013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Verdecchia P, Dagenais G, Healey J, Gao P,
Dans AL, Chazova I, Binbrek AS, Iacobellis G, Ferreira R, Holwerda
N, et al Ongoing Telmisartan Alone and in Combination With Ramipril
Global Endpoint TrialTelmisartan Randomized AssessmeNt Study in ACE
iNtolerant subjects with cardiovascular Disease Investigators, :
Blood pressure and other determinants of new-onset atrial
fibrillation in patients at high cardiovascular risk in the Ongoing
Telmisartan Alone and in Combination With Ramipril Global Endpoint
Trial/Telmisartan Randomized Assessment Study in ACE intolerant
subjects with cardiovascular Disease studies. J Hypertens.
30:1004–1014. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Takagi H and Umemoto T: Telmisartan
increases adiponectin levels: A meta-analysis and meta-regression
of randomized head-to-head trials. Int J Cardiol. 155:448–451.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nilsson PM: Target blood pressure in
diabetes patients with hypertension - what is the accumulated
evidence in 2011? J Zhejiang Univ Sci B. 12:611–623. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hong SJ, Choi SC, Ahn CM, Park JH, Kim JS
and Lim DS: Telmisartan reduces neointima volume and pulse wave
velocity 8 months after zotarolimus-eluting stent implantation in
hypertensive type 2 diabetic patients. Heart. 97:1425–1432. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Toyama K, Nakamura T, Kataoka K, Yasuda O,
Fukuda M, Tokutomi Y, Dong YF, Ogawa H and Kim-Mitsuyama S:
Telmisartan protects against diabetic vascular complications in a
mouse model of obesity and type 2 diabetes, partially through
peroxisome proliferator activated receptor-γ-dependent activity.
Biochem Biophys Res Commun. 410:508–513. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cowan BR, Young AA, Anderson C, Doughty
RN, Krittayaphong R, Lonn E, Marwick TH, Reid CM, Sanderson JE,
Schmieder RE, et al ONTARGET Investigators, : Left ventricular mass
and volume with telmisartan, ramipril, or combination in patients
with previous atherosclerotic events or with diabetes mellitus
(from the ONgoing Telmisartan Alone and in Combination With
Ramipril Global Endpoint Trial [ONTARGET]). Am J Cardiol.
104:1484–1489. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chang WT, Cheng JT and Chen ZC:
Telmisartan improves cardiac fibrosis in diabetes through
peroxisome proliferator activated receptor δ (PPARδ): From bedside
to bench. Cardiovasc Diabetol. 15:1132016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Toma I, Kim PJ, Dash R, McConnell MV,
Nishimura D, Harnish P and Yang PC: Telmisartan in the diabetic
murine model of acute myocardial infarction: Dual contrast
manganese-enhanced and delayed enhancement MRI evaluation of the
peri-infarct region. Cardiovasc Diabetol. 15:24–25. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen AX, Jerums G, Baqar S, Lambert E,
Somarajah G, Thomas G, O'Callaghan C, MacIsaac RJ and Ekinci EI:
Short-term dietary salt supplementation blunts telmisartan induced
increases in plasma renin activity in hypertensive patients with
type 2 diabetes mellitus. Clin Sci (Lond). 129:415–422. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chaudagar KK and Mehta AA: Effect of
telmisartan on VEGF-induced and VEGF-independent angiogenic
responsiveness of coronary endothelial cells in normal and
streptozotocin (STZ)-induced diabetic rats. Clin Exp Hypertens.
36:557–566. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rizos CV, Liberopoulos EN, Tellis K,
DiNicolantonio JJ, Tselepis AD and Elisaf MS: Combining
rosuvastatin with angiotensin-receptor blockers of different
PPARγ-activating capacity: Effects on high-density lipoprotein
subfractions and associated enzymes. Angiology. 66:36–42. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Antoniou T, Camacho X, Yao Z, Gomes T,
Juurlink DN and Mamdani MM: Comparative effectiveness of
angiotensin-receptor blockers for preventing macrovascular disease
in patients with diabetes: A population-based cohort study. CMAJ.
185:1035–1041. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Michel MC, Foster C, Brunner HR and Liu L:
A systematic comparison of the properties of clinically used
angiotensin II type 1 receptor antagonists. Pharmacol Rev.
65:809–848. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dehghan M, Mente A, Teo KK, Gao P, Sleight
P, Dagenais G, Avezum A, Probstfield JL, Dans T and Yusuf S;
Ongoing Telmisartan Alone and in Combination With Ramipril Global
End Point Trial (ONTARGET)/Telmisartan Randomized Assessment Study
in ACEI Intolerant Subjects With Cardiovascular Disease (TRANSCEND)
Trial Investigators, : Relationship between healthy diet and risk
of cardiovascular disease among patients on drug therapies for
secondary prevention: A prospective cohort study of 31546 high-risk
individuals from 40 countries. Circulation. 126:2705–2712. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Volpe M: Preventing cardiovascular events
with angiotensin II receptor blockers: A closer look at telmisartan
and valsartan. Expert Rev Cardiovasc Ther. 10:1061–1072. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guo Z, Zhang R, Li J and Xu G: Effect of
telmisartan on the expression of adiponectin receptors and
nicotinamide adenine dinucleotide phosphate oxidase in the heart
and aorta in type 2 diabetic rats. Cardiovasc Diabetol. 11:94–111.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kappert K, Böhm M, Schmieder R, Schumacher
H, Teo K, Yusuf S, Sleight P and Unger T; ONTARGET/TRANSCEND
Investigators, : Impact of sex on cardiovascular outcome in
patients at high cardiovascular risk: Analysis of the Telmisartan
Randomized Assessment Study in ACE-Intolerant Subjects With
Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan
Alone and in Combination With Ramipril Global End Point Trial
(ONTARGET). Circulation. 126:934–941. 2012. View Article : Google Scholar : PubMed/NCBI
|
